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Previewsdetected will certainly aid in elucidating
their structures, identifying their biosyn-
thetic pathways, and determining their
role in M. tuberculosis biology.
Importantly, the quantitative and repro-
ducible data generated from this LC-MS
approach will allow for future comparative
studies to probe dynamic changes in the
global lipidome. It is clear that changes
in lipid content allow for M. tuberculosis
to adapt to a variety of different condi-
tions, including upon encountering stress
(Cunningham and Spreadbury, 1998) and
during infection (Kondo et al., 1970). The
technology developed by Layre et al.
(2011) will allow for a systems approach
to study these types of dynamic changes.
Indeed, the authors have demonstrated
that this method can sensitively detect
mycobacterial species even in extracts
from M. tuberculosis-infected tissue
‘‘contaminated’’ with eukaryotic lipids.
Understanding the changes that occur to
the lipidome during infection or conditions
that mimic infection such as reactive
oxygen or nitrogen stress, low iron, and1518 Chemistry & Biology 18, December 23,hypoxia, will be important to understand
the role of lipids in virulence and the
metabolic changes that occur during
infection.
Approaches to globally monitor nu-
cleic acids, proteins, and the water-
soluble metabolites within cells have
revolutionized our understanding of
M. tuberculosis biology. The absence
of similar methodologies to monitor
hydrophobic lipids has been a glaring
deficiency, especially given the impor-
tant roles of these molecules during
infection. The lipidomic platform pio-
neered by Layre et al. (2011) will allow
researchers to finally probe this final
frontier of the mycobacterial cell.REFERENCES
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Although the clinical safety of compounds targeting the core components of the Wnt signaling pathway
remains to be determined, a simple in vivo chemical screen identifies small molecules that inhibit Wnt
signaling in a cell type-specific manner (Ni et al., this issue of Chemistry & Biology).The Wnt/b-catenin signaling pathway is
undoubtedly one of the most prominent
biological pathways. In 1987, Roel
Nusse’s group showed that the mouse
mammary oncogene int-1 was the
homolog of the Drosophila segment
polarity gene wingless (Rijsewijk et al.,
1987). Thereafter, the name ‘‘Wnt,’’
derived from the combined names of
wingless and int-1, rightly signifies its
myriad roles in regulating embryonic
development and the homeostasis of
adult tissues. In addition, aberrant Wnt
signaling may cause cancers and otherdiseases (Clevers, 2006). Although in-
hibitors that target Wnt signaling ubiqui-
tously may seemingly have the broadest
utility, their potential for pleiotropic effects
on adult tissues remains a concern.
Conceivably, inhibitors that target cell
type-specific components of the Wnt
pathway may have better safety profiles.
Why has such a compound not turned
up in the screens that have been per-
formed? Is discovery of tissue-specific
Wnt inhibitors possible? In this issue, Ni
et al. (2011) provide the first example
of a tissue-specific Wnt inhibitor anddemonstrate its potential for expanding
cardiac progenitor cells.
Myocardial infarctions cause significant
clinical problems in Western society.
Thus, cardiogenic compounds are sought
after for they may reactivate cardiac
progenitors and repopulate infarcted
myocardium. Several signaling pathways
have been implicated in the genesis of
cardiac progenitors from pluripotent
stem cells. Moreover, a number of tar-
geted and screening approaches for the
identification of cardiogenic compounds
have been reported (Hao et al., 2008;
BA
Figure 1. Two Ways to Discover Cardiogenic Small Molecules
The top panel shows the method utilized by Ni et al. (2011) for discovering cardiogenic small molecules.
The bottom panel shows a more common method. In the top panel, cardiogenic compound A is identified
via an in vivo chemical screen in embryonic zebrafish. It induces an enlarged heart phenotype without
affecting any other aspects of embryonic development. Subsequently, compound A may show a similar
cardiogenic effect on mouse ES cells. In the bottom panel, cardiogenic compound B is identified via
a cell-based screen in mouse ES cells. Subsequently, compound Bmay show a similar cardiogenic effect
in embryonic zebrafish while simultaneously inducing additional effects on some other aspects of embry-
onic development.
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In the hope of discovering additional
cardiogenic compounds, Ni et al. (2011)
decided to shy away from the common
approaches and conducted an unbiased
chemical screen using embryonic
zebrafish. Traditionally a favorable model
for developmental biologists, zebrafish
have gained popularity in the chemical
biology field in the recent years. Embry-
onic or larval zebrafish can be adopted
in various kinds of low to high-throughput
screening methodology. Assays relying
on more complex biological interactions
may be developed in vivo. Furthermore,
a whole-organism screening strategy
enables the detection of desirable effects
in the target tissues and any potential
unwanted effects in other tissues simulta-
neously (Figure 1). In this study, Ni et al.
(2011) conducted a simple chemical
screen using an existing transgenic ze-
brafish line that exhibited green fluores-
cent cardiomyocytes to search for com-
pounds that caused an enlarged heart
phenotype. The authors identified three
structurally-related compounds named
Cardionogens that could do so without
affecting any other aspects of embryonic
development.
Ni et al. (2011) first confirmed that
Cardionogen increased heart sizes by
increasing cardiac progenitors and not
by other less desirable mechanisms(such as increasing cardiomyocyte sizes).
Next, an important hint of the mode of
action of Cardionogen emerged from its
effective time window during embryonic
development. Although Cardionogen
treated after gastrulation enhanced car-
diogenesis, it adversely affected cardio-
genesis if treated before gastrulation.
Interestingly, the biphasic pattern of Car-
dionogen’s effects is opposite to the
known biphasic pattern of the Wnt effects
on heart development (Naito et al., 2006;
Ueno et al., 2007). This finding compelled
the authors to perform a series of ex-
periments, and they concluded that Car-
dionogen inhibited the Wnt/b-catenin
signaling pathway in zebrafish heart and
in mouse ES cells.
In the past two decades, most of the
key players of the Wnt signaling pathway
have been identified, such as the Wnt
ligands, their transmembrane receptors,
coreceptors, the b-catenin destruction
complex and the Tcf/b-catenin transcrip-
tion factors that ultimately activates the
Wnt target genes (Clevers, 2006). In addi-
tion, Wnt signaling may be modified by
other cell type-specific factors, though
the identities and the regulation of these
modifiers are far less clear. Several
classes of small molecule Wnt inhibitors
already exist today (Barker and Clevers,
2006; Chen et al., 2009; Huang et al.,
2009). Previously, common strategies forChemistry & Biology 18, December 23, 2011 ªdiscovering small molecule Wnt antago-
nists include in vitro assays to identify
compounds that disrupt b-catenin-Tcf
interaction and cell-based assays to iden-
tify compounds that inhibit Wnt/b-cate-
nin-dependent gene activation. These
methods have uncovered a number of
potent Wnt antagonists that target the
core components of the Wnt pathway
(Barker and Clevers, 2006; Chen et al.,
2009; Huang et al., 2009).
Although aberrant Wnt signaling is the
key feature of some cancers and
diseases, Wnt signaling also plays essen-
tial roles in renewing various adult tis-
sues (Clevers, 2006). Thus, drugs that
inhibit Wnt signaling ubiquitously may
exert adverse effects on some renewing
tissues. A line of evidence supporting
this hypothesis came from the studies of
a class of Wnt inhibitors called IWRs
(Chen et al., 2009). It has been shown
that, in addition to potently blocking
Wnt/b-catenin activities in several types
of cancer cells, IWRs also effectively
blocked tailfin regeneration and renewal
of intestinal epithelium in zebrafish (Chen
et al., 2009). In this issue, Ni et al. (2011)
also investigated the effects of IWR-1 on
cardiogenesis. They showed that, like
Cardionogen, IWR-1 induced cardiogenic
effects on embryonic zebrafish and
mouse ES cells. However, unlike Cardio-
nogen, IWR-1 also disrupted develop-
ment of embryonic posterior structures
and resulted in a single-chambered heart
(Figure 1). These results exacerbate the
concerns for developing some existing
Wnt inhibitors clinically.
From a clinical standpoint, regenerative
medicines may require a more stringent
safety profile than anticancer therapeu-
tics do. In the report by Ni et al. (2011),
the authors provided several pieces of
information suggesting that Cardionogen
antagonizes Wnt signaling in a cell type-
specific manner, making it a desirable
drug candidate. For example, Cardiono-
gen inhibited Wnt3a-induced TOPflash
luciferase activities in mouse ES cells
but not in HEK cells. Moreover, Cardiono-
gen reversed Wnt8-induced cardiac hy-
potrophy but not the small eye pheno-
type. Based on their results, the authors
speculated that Cardionogen may target
an intracellular or nuclear factor that
modifies Wnt signaling. Unfortunately,
the target of Cardionogen remains
unidentified. Furthermore, it is not yet2011 Elsevier Ltd All rights reserved 1519
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cardiac progenitors are. Although Cardio-
nogen stimulates cardiac differentiation
in mouse ES cells, until the ethical and
practical issues of stem cell therapy are
resolved, testing whether Cardionogen
may directly induce the expansion of the
adult cardiac progenitors in vivo is inevi-
tably the final way to realistically assess
its therapeutic potential.
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